Coatings and soaks for medical prosthetic devices comprising taurinamide derivatives and carboxylic acids and/or salts thereof
원문보기
IPC분류정보
국가/구분 |
United States(US) Patent
등록
|
국제특허분류(IPC7판) |
|
출원번호 |
US-0552198
(2000-04-19)
|
발명자
/ 주소 |
|
출원인 / 주소 |
|
대리인 / 주소 |
|
인용정보 |
피인용 횟수 :
7 인용 특허 :
3 |
초록
▼
The present invention relates to a method of inhibiting or preventing infection and blood coagulation in or near a medical prosthetic device after the device has been inserted in a patient by administering to the device a pharmaceutically effective amount of a composition having: (A) at least one
The present invention relates to a method of inhibiting or preventing infection and blood coagulation in or near a medical prosthetic device after the device has been inserted in a patient by administering to the device a pharmaceutically effective amount of a composition having: (A) at least one taurinamide derivative, and (B) at least one compound selected from the group consisting of biologically acceptable acids and biologically acceptable salts thereof, whereby there are no systemic anti-clotting and no systemic biocidal effects.
대표청구항
▼
1. A medical prosthetic device coated with a composition comprising: (A) at least one taurinamide derivative; (B) at least one biologically acceptable acid; and (C) at least one biologically acceptable salt of said acid, wherein said acid is present in sufficient amount to bring the pH of the c
1. A medical prosthetic device coated with a composition comprising: (A) at least one taurinamide derivative; (B) at least one biologically acceptable acid; and (C) at least one biologically acceptable salt of said acid, wherein said acid is present in sufficient amount to bring the pH of the composition into a range of from about 3.5 to about 7.0. 2. A medical prosthetic device coated with a composition comprising: (A) at least one antimicrobial compound of the formula wherein R1 is hydrogen or alkyl and R2 is hydrogen, alkyl, or a group of the formula (B) at least one biologically acceptable acid; and (C) at least one biologically acceptable salt of said acid, wherein said acid is present in sufficient amount to bring the pH of the composition into a range of from about 3.5 to about 7.0; wherein the composition is included in a pharmaceutically effective amount for preventing or inhibiting infection and blood coagulation. 3. The device of claim 2 wherein the antimicrobial compound is taurolidine. 4. The device of claim 2 wherein the antimicrobial compound is taurultam. 5. The device of claim 2 wherein the biologically acceptable acid or salt thereof is selected from the group consisting of acetic acid, citric acid, fumaric acid, maleic acid, hydrochloric acid, malic acid, phosphoric acid, tartaric acid, ascorbic acid, boric acid, lactic acid, ethylenediaminetetraacetic acid (EDTA), ethylene glycol-bis{β-aminoethyl ether}-N,N,N',N'-tetraacetic acid, diethylenetriamine pentaacetic acid, ammonium phosphate, potassium citrate, potassium metaphosphate, sodium acetate, sodium citrate, sodium lactate, and sodium phosphate. 6. The device of claim 2 wherein the biologically acceptable acid or salt thereof is selected from the group consisting of citric acid, an alkali metal salt of citric acid, and mixtures thereof. 7. The device of claim 2 wherein the biologically acceptable acid or salt thereof is selected from the group consisting of ethylenediaminetetraacetic acid, an alkali metal salt thereof, and mixtures of the acid and the salt. 8. The device of claim 2 wherein the composition further comprises polyvinyl pyrrolidone. 9. The device of claim 2 wherein the composition further comprises a parenterally acceptable polyol. 10. The device of claim 2 wherein the composition further comprises a broad spectrum antibiotic substance. 11. The device of claim 10 wherein the broad spectrum antibiotic substance is selected from the group consisting of a β-lactam antibiotic, a tetracycline antibiotic, a macrolide antibiotic, a polypeptide antibiotic, and an aminoglycoside antibiotic. 12. The device of claim 11 wherein the broad spectrum antibiotic substance is an aminoglycoside antibiotic. 13. The device of claim 12 wherein the broad spectrum antibiotic substance is gentamicin. 14. The device of claim 2 wherein the medical prosthetic device is a catheter. 15. The device of claim 14 wherein the catheter is a hemodialysis catheter. 16. The device of claim 2 wherein the medical prosthetic device is a port. 17. The device of claim 16 wherein the catheter is a hemodialysis port.
이 특허에 인용된 특허 (3)
-
Raad Isaam (Houston TX) Sherertz Robert (Winston-Salem NC), Non-glycopeptide antimicrobial agents in combination with an anticoagulant, an antithrombotic or a chelating agent, and.
-
Reinmller Johannes (Erhardtstrasse 40 D - 7900 Ulm DEX), Novel use of taurolin.
-
Pfirrmann Rolf W. (Lucerne CHX), Pharmaceutical compositions.
이 특허를 인용한 특허 (7)
-
Reinmuller, Johannes; Dirting, Kay, Antiinfective composition.
-
Prosl, Frank R., Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin.
-
Kite, Peter; Hatton, David, Antiseptic compositions, methods and systems.
-
Ash, Stephen R.; Steczko, Janusz; Swanson, Gary L., Catheter lock solution comprising citrate and a paraben.
-
Ash, Stephen R.; Steczko, Janusz; Swanson, Gary L., Catheter lock solution comprising citrate and a paraben.
-
Ash, Stephen R.; Steczko, Janusz; Swanson, Gary L., Catheter lock solution comprising citrate and a paraben.
-
Hirschmann, Aaron; Hacker, Robert; Fesus, Robert; Grimes, Christopher J; Talbot Griffith, Hannah M, Tamper evident closure container.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.